Sysmex and Roche Extend Hematology Alliance

Sysmex Corporation (Kobe, Japan) and Roche (Basel, Switzerland) signed a restated 10 years distribution, sales, and services agreement (DSS Agreement). The previous distributorship, sales, and services agreement will extend for another 10 years.

Roche will continue to distribute Sysmex hematology products, including instruments, reagents, and data management solutions in selected countries and regions. These include Spain, Turkey, Greece, South Africa, Russia, Finland, Baltic Territory, Brazil, Mexico, Chile, Argentina, Uruguay, Colombia, Peru, Ecuador, Venezuela, Central America, Australia, and New Zealand.

The recently released new XN series from Sysmex with its modular and scalable system design enables customer access to a full menu across customer segments from small to large workloads. Concurrent with Roche’s future platform strategy, the new Sysmex XN series contributes to Roche’s concept of addressing the various needs of today’s laboratories with customized modular solutions. The renewed agreement allows both companies to apply their strengths more effectively.

Since entering into the DSS Agreement in 1999, Sysmex and Roche have combined their mutual strengths to expand market share while building a positive relationship.

Hisashi Ietsugu, president and CEO of Sysmex Corp. commented, "Based on Sysmex’ industry leadership allied with Roche’s unique position as the global market leader in in-vitro diagnostics, the collaboration underlines our objective of bringing a maximum of industry expertise in hematology to health professionals. This unique synergy supports both companies’ objectives to continue to grow above market."

Sysmex Corporation is a leader in clinical laboratory testing of blood, urine and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems as part of a comprehensive service and support system.

Roche Professional Diagnostics is Roche’s market-leading business area of integrated, modular, and highly efficient testing solutions for clinical and immune in vitro diagnostics for centralized and decentralized settings. Roche is also a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life, and survival of patients.

Related Links:
Sysmex Corporation
Roche